Page 203 - Genomic Medicine in Emerging Economies

192 Index

L N biomarker
Latin American countries, and National Cancer Comprehensive in general population, 134
information, 150
populations, 104 Network (NCCN), 29, 34
Latin American Program of the National Genomic Data System, 142 cost-effectiveness ratio, 155
testing, 175
Human Genome (PLAGH), 71 National health care systems, 11
working group, 147, 149
Legal framework, 9 National Human Genome Research PHY906, interaction of, 60
Legislation, 2, 163 Institute, 14, 49 PLAGH. See Latin American Program
Life-threatening adverse drug Neurological diseases, in Latin of the Human Genome
reactions, 1 America, 72
(PLAGH)
Long QT syndrome, 143 advances in molecular genetics Policymakers, 9
Low-middle-income countries of, 72–83 Polymerase chain reaction
(LMIC), 49 epidemiological impact of, 72
technique, 101–114
Lynch syndrome, 31 overview of prevalence of, 73 Predictive, preventive, and
clinical and genetic features, 31 Neuropsychiatric disorders (NPDs), personalized (precision)
in Latin America 101, 113 medicine (PPPM), 60
collaborative network, 34 data about prevalence, heritability, diagnosis and treatment of
hereditary Lynch syndrome and burden, 87 suboptimal health, 40
registries in, 32 in Latin America,
integrative concept, 61
mutation, molecular and clinical pharmacogenetics, 79–86 Prenatal diagnosis, 117
profile, 33–36 local validation of additional
published data from Latin America psychosocial and clinical Private investments, 132
Programed cell death, 38
Lynch syndrome spectrum, 85 scales, 89 Protein truncation test (PTT), 71
Neuropsychiatric endophenotypes,
M in Latin America, 76 Proteomics, 11
Psychiatric disorders, in Latin
Major depressive disorder (MDD), 72 molecular genetics and, 76 America, 72
Manpower, 14 published association studies advances in molecular genetics
Mapping disease genes, 13 for candidate genes and, 85 of, 75
Marfan syndrome, 143 Neuropsychiatric genetics (NPG), 101 overview of prevalence of, 73
Markov decision analytic model, 134 creation of Latin American published association studies
Markov model, 134 networks for, 87 for candidate genes
MDD. See Major depressive disorder funding for research in Latin and, 107
(MDD) American countries, 87 Psychiatric drugs, 90
Medical errors, 145 Next-generation sequencing (NGS), Public health care, 1
Medical testing, 1 29, 62, 113, 139 Public health genomics, 13,
Members of the GMA Economic facilities, 71 146, 147
Evaluation in Genomic NGS. See Next-generation sequencing working group, 153
Medicine Working Group, 156 (NGS) Public health programs, 20
Mendelian sense, 153 Noninvassive prenatal test, 117
Mental retardation, 143 Northern Caucasus populations, 134
NPDs. See Neuropsychiatric disorders Q
Metabolomics, 11
Migraine, 72 (NPDs) Quality-adjusted life years
Molecular biology, 108 NPG. See Neuropsychiatric genetics (QALY), 133
Molecular genetics, 108 (NPG) R
Multicenter projects, 9
Multi-omics integrative biology O Random amplified polymorphic
research, 62 Oncology, 50 DNA (RAPD) technique, 58
Mutation, 101 Over-the-counter (OTC) genetic Randomized evaluation of long-term
APC gene mutations, in Latin tests, 154 anticoagulation therapy
American studies, 87 (RE-LY), 134
founder mutation P Regeneron Genetics Center
in genes BRCA1 and BRCA2, 54 Pediatric disorders, 49 (RGC), 183
in PSEN1 gene, 161 Personalized medicine, 115, 145 Reimbursement policies, 2
screening, in cancer genes, 40 Pharmacogenomics, 90, 132, 145, RELAGH organizing meeting, 71
MUTYH Associated Polyposis (MAP), 36 146, 147, 176 Research centers, 3